Nvidia has introduced the BioNeMo Agent Toolkit, a software suite designed to enhance AI capabilities in biology, chemistry, genomics, and drug discovery. The toolkit integrates Nvidia's life sciences libraries, models, and computing tech to enable AI agents to perform scientific tasks, analyze data, and recommend actions. Over 50 organizations, including Lilly, Natera, and OpenAI, are already using it to accelerate research workflows. This innovation aims to reduce the time needed for computational experiments and improve scientific discovery efficiency.
The SPDR NYSE Technology ETF (XNTK) has significantly outperformed the Invesco QQQ Trust (QQQ) over the past year, returning 51.65% compared to QQQ's 28.43%. XNTK uses an equal-weight approach focusing solely on about 35 tech leaders, capturing broad...
Sanjeev Sharma forecasts the S&P 500 will finish 2026 slightly below its starting point due to weak consumer fundamentals like stagnant wage growth, high inflation, elevated gas prices, and rising interest rates. His disposable income-based model hig...
The Direxion Daily Technology Bull 3X ETF (TECL) is rated Buy due to easing inflation and a positive outlook for the Nasdaq-100, driven by growing AI infrastructure investments and increasing influence of smaller AI-related companies beyond the major...
The State Street SPDR Portfolio S&P 500 ETF (SPYM) has been selected as the default investment for the new Trump Accounts program, which provides eligible newborns with a $1,000 Treasury contribution invested in this fund. SPYM tracks the S&P 500 ind...
Nvidia CEO Jensen Huang refuted reports claiming delays in the production of the Vera Rubin AI accelerator platform, confirming that production is already underway with large volumes expected. This statement counters a report from SemiAnalysis sugges...
